# Teleflex Publishes 2024 Global Impact Report Canonical URL: https://biopharmsignal.com/news/TFX/teleflex-publishes-2024-global-impact-report-5d2861ec Ticker: TFX Company: Teleflex Source: Teleflex Published: 2025-05-19 10:30 EST ## Summary Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program... ## Article Body Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). “This year’s Global Impact Report is a demonstration of Teleflex’s continued journey in Corporate Social Responsibility, evident in both the progress we have made and in our targets that we continue to set and work toward” said Cam Hicks, Corporate Vice President and Chief Human Resources Officer. “As the Chair of our CSR Steering Committee, it’s an honor to watch our CSR program continue to grow in recognition among our stakeholders and to see the pride it brings to our employees, who believe in working for a company that genuinely cares about its impact to our planet, our products and our people.” The 2024 Global Impact Report outlines accomplishments and plans for each of the company’s four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance. Highlights from this year’s report include: Materiality Assessment: We conducted a double materiality assessment in line with the E.U. Corporate Sustainability Reporting Directive. This assessment determines what Teleflex will have to disclose to the E.U. Commission and gives us an opportunity to ensure our CSR strategy and focus areas remain appropriate. World Economic Forum: Teleflex signed on to the World Economic Forum Zero Health Gaps Pledge, under which Teleflex has committed to ensuring equal and equitable access to healthcare. Carbon Disclosure Project: We submitted our CDP (formerly Carbon Disclosure Project) Climate Questionnaire, which contains data points pertaining to our greenhouse gas emissions, starting with our baseline year (2019) and 2023 progress against our validated Science-Based Targets. Environmental Management Systems: In 2024, we have 6 sites that were ISO 14001 certified, and we will look to add more in the future. Read the full 2024 Global Impact Report at https://teleflex.com/usa/en/about-us/csr/index.html . About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2025 Teleflex Incorporated. All rights reserved. Contacts: Teleflex Lawrence Keusch Vice President, Investor Relations and Strategy Development investor.relations@teleflex.com 610-948-2836 ## Recent Company News - 2026-01-08 11:30 EST — [Teleflex Announces Leadership Transition](https://biopharmsignal.com/news/TFX/teleflex-announces-leadership-transition-d572754c) — Source: Teleflex - 2025-12-09 14:04 EST — [Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion](https://biopharmsignal.com/news/TFX/teleflex-announces-sale-of-acute-care-interventional-urology-and-oem-businesses--da92348c) — Source: Teleflex - 2025-11-14 11:30 EST — [Teleflex to Present at the Jefferies Global Healthcare Conference in London](https://biopharmsignal.com/news/TFX/teleflex-to-present-at-the-jefferies-global-healthcare-conference-in-london-78b44fb9) — Source: Teleflex - 2025-11-06 11:45 EST — [Teleflex Announces Quarterly Dividend](https://biopharmsignal.com/news/TFX/teleflex-announces-quarterly-dividend-b49b5009) — Source: Teleflex - 2025-11-06 11:30 EST — [Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook](https://biopharmsignal.com/news/TFX/teleflex-reports-third-quarter-financial-results-and-full-year-2025-outlook-7e2975be) — Source: Teleflex ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)